Development of a Level A in Vitro-in Vivo Correlation for Veliparib (ABT-888) Extended Release Tablet Formulation

[1] Wagner LM(2015)Profile of veliparib and its potential in the treatment of solid tumors OncoTargets Ther 8 1931-1939

[2] Donawho CK(2007)ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin. Cancer res. Off. J. Am. Assoc Cancer Res 13 2728-2737

[3] Luo Y(2005)Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors Nat Rev Drug Discov 4 421-440

[4] Luo Y(2014)Population pharmacokinetic modeling of veliparib (ABT-888) in patients with non-hematologic malignancies Clin Pharmacokinet 53 479-488

[5] Penning TD(2015)A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - an NRG oncology/gynecologic oncology group study Gynecol Oncol 137 386-391

[6] Bauch JL(2006) - Pharm 9 169-189

[7] Bouska JJ(2013) correlation: from theory to applications. J. Pharm. Pharm. Sci. Publ. Can. Soc. pharm. Sci. Soc. can. Sci Pharm Res 30 179-190

[8] Jagtap P(undefined)Use of undefined undefined undefined-undefined

[9] Szabó C(undefined)- undefined undefined undefined-undefined

[10] Salem AH(undefined) correlation to predict the pharmacokinetics of several products containing a BCS class 1 drug in extended release matrices undefined undefined undefined-undefined

[1] Wagner LM(2015)Profile of veliparib and its potential in the treatment of solid tumors OncoTargets Ther 8 1931-1939

[2] Donawho CK(2007)ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin. Cancer res. Off. J. Am. Assoc Cancer Res 13 2728-2737

[3] Luo Y(2005)Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors Nat Rev Drug Discov 4 421-440

[4] Luo Y(2014)Population pharmacokinetic modeling of veliparib (ABT-888) in patients with non-hematologic malignancies Clin Pharmacokinet 53 479-488

[5] Penning TD(2015)A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - an NRG oncology/gynecologic oncology group study Gynecol Oncol 137 386-391

[6] Bauch JL(2006) - Pharm 9 169-189

[7] Bouska JJ(2013) correlation: from theory to applications. J. Pharm. Pharm. Sci. Publ. Can. Soc. pharm. Sci. Soc. can. Sci Pharm Res 30 179-190

[8] Jagtap P(undefined)Use of undefined undefined undefined-undefined

[9] Szabó C(undefined)- undefined undefined undefined-undefined

[10] Salem AH(undefined) correlation to predict the pharmacokinetics of several products containing a BCS class 1 drug in extended release matrices undefined undefined undefined-undefined